Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

 Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

**The Biotech Giant Just Reminded Wall Street That It Was Never Just a Pandemic Story — And Investors Are Finally Listening**

---

## The Moment That Changed the Narrative

Let me tell you about a woman named Karen. She’s a portfolio manager at a mid-sized investment firm in Boston. She’s been watching Moderna for years. She remembers the pandemic days when the stock was flying high, and she remembers the crash that followed when the world moved on from Covid.

For most of 2024 and 2025, Karen couldn’t get her colleagues to take Moderna seriously. “It’s a one-trick pony,” they’d say. “Covid is over. What else do they have?”

She’d try to explain about the pipeline. About the mRNA platform. About the cancer vaccine. But nobody wanted to hear it. The stock was dead, and that was that.

Then August 19, 2026 happened. Moderna announced positive Phase 3 data for its personalized cancer vaccine, and the stock **nearly tripled in a single day**. Karen’s phone started ringing. Suddenly, everyone wanted to talk about Moderna.

And then this week, something even more interesting happened. On Wednesday, September 23, Moderna CEO Stéphane Bancel took the stage at Bernstein’s annual healthcare conference and said something that cut to the heart of the debate.

“Moderna has never been a Covid vaccine company,” he said. “We’re an mRNA platform company”.

The stock hit a **52-week high of $192.31** that day. It closed the week at **$194.82**, up nearly **7%** on Thursday alone. Year-to-date, the stock is up more than **500%**.

Karen was right. And now the rest of the market is playing catch-up.

---

## The Numbers: A Stock on Fire

Let’s get the raw data on the table, because the magnitude of this move is genuinely historic.

**The Price Action:**

Moderna shares closed Thursday, September 24, at **$194.82**, up **6.98%** for the day. The stock hit an intraday high of **$195.71** — a new 52-week high. The previous close was $182.11.

But the daily move is just the tip of the iceberg.

**The Longer-Term Picture:**

- **1-week return:** +25%

- **1-month return:** +31%

- **3-month return:** +205%

- **Year-to-date:** +517%

- **1-year return:** +606%

Over the past 52 weeks, Moderna has traded between a low of **$22.28** and a high of **$195.71**. That’s a range of nearly **800%**.

The stock now carries a **market capitalization of approximately $72.7 billion**.

**The Volume:**

Trading volume has been elevated, with **16.4 million shares** changing hands on Thursday alone — close to the three-month average of 16.7 million. On Wednesday, volume hit **17.7 million**, and on Monday, it was **21 million**. Investors are paying attention.

---

## Why This Is Happening: The Cancer Vaccine Story

To understand why Moderna is surging, you have to understand what happened in August.

On August 19, 2026, Moderna and its partner Merck announced that their personalized cancer vaccine, **intismeran autogene**, had achieved a major breakthrough in a Phase 3 trial. The study evaluated the vaccine in combination with Merck’s Keytruda as an adjuvant treatment for patients with resected melanoma — skin cancer that had been surgically removed but carried a high risk of recurrence.

The results showed that the combination **prevented cancer from returning more effectively than Keytruda alone**. The trial met both its primary endpoint and a secondary endpoint of distant metastasis-free survival at the first interim analysis.

This wasn’t a small trial. It involved approximately **1,100 patients** in a rigorously controlled, blinded study.

The stock reaction was explosive. Moderna shares **nearly tripled in a single session** — a move that made headlines across Wall Street.

“The Phase 3 results marked a major success for the field of personalized cancer vaccines,” noted Leerink Partners analyst Lili Nsongo, who added that previous failures in the field “paint a complex picture for mRNA cancer vaccines”.

What makes intismeran different is its **personalization**. The vaccine is engineered to flag dozens of mutations unique to each patient’s tumor. It’s not a one-size-fits-all treatment. It’s a custom-built therapy designed for each individual’s cancer.

“Moderna owns the proprietary work involved in selecting the 34 mutations included in each individualized cancer vaccine,” Bancel explained at the Bernstein conference. External partners provide DNA sequencing data, but Moderna handles the downstream analysis and selection process.

---

## Beyond Covid: The Platform Story

But here’s the thing that Bancel wants investors to understand: Covid was never the point. It was an opportunity. A validation. A proof of concept.

“Moderna has been an mRNA platform company since its founding,” Bancel said. The Covid vaccine was “an unplanned but necessary response to the pandemic rather than the company’s long-term strategy”.

The company now has **five approved products** and two product launches planned for this year. That’s up from zero in 2020.

**The Respiratory Vaccine Business**

Moderna’s commercial portfolio includes:

- **Spikevax** (Covid-19 vaccine), approved in 40 countries

- **mNEXSPIKE** (next-generation Covid vaccine), approved in the U.S. and Canada

- **mRESVIA** (RSV vaccine), approved in 40 countries

- **mRNA-1010** (seasonal flu vaccine), submissions completed in major markets

- **mRNA-1083** (flu + Covid combination vaccine), under review in Europe and Canada

The company expects growth from long-term partnerships in the UK, Canada, and Australia, and is targeting entry into the flu vaccine market in 2027. By 2028, Moderna anticipates a first-to-market flu/Covid combination vaccine and a potential norovirus vaccine, expanding its seasonal franchise to as many as **six approved products**.

**The Oncology Pipeline**

Intismeran is just the beginning.

Moderna has **eight Phase 2 and Phase 3 clinical trials underway** for the cancer vaccine across multiple tumor types, including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

Chief Development Officer David Berman outlined the breadth of the program at the Bernstein conference. There are ongoing studies in:

- Lung cancer (three Phase 3 trials)

- Renal cell carcinoma

- Bladder cancer

- Pancreatic cancer

- Gastric cancer

The company is also studying intismeran in earlier stages of disease, including a Phase 3 trial in stage 1 lung cancer and a randomized Phase 2 trial in non-muscle-invasive bladder cancer.

Berman noted that Moderna’s view is that the treatment **may be active without a PD-1 inhibitor** — potentially creating opportunities in settings where checkpoint inhibitors are not commonly used.

**The Rare Disease Pipeline**

Beyond oncology, Moderna is advancing programs in rare genetic diseases. Bancel said the company expects **pivotal data for propionic acidemia by year-end**. He described the program as the first of what could become a broader liver-focused rare-disease franchise, using mRNA to direct the liver to produce missing or deficient proteins.

Moderna has published work involving more than **12 rare genetic liver-disease models** and intends to advance additional programs using the same delivery approach and manufacturing infrastructure.

---

## The Next Catalyst: ESMO Presentations

If you’re trying to understand what could drive the stock from here, mark your calendar for late October.

Moderna announced Monday that **three abstracts on intismeran autogene** have been accepted for presentation at the **European Society for Medical Oncology (ESMO) Congress 2026**, to be held October 23-27 in Madrid, Spain.

This is one of the largest oncology conferences in the world. And the presentations will provide the first full, detailed look at the data that caused the stock to nearly triple in August.

**The three presentations:**

1. **The flagship presentation:** Full Phase 3 results for intismeran autogene plus Keytruda as adjuvant treatment for resected melanoma. This is the data that started everything.

2. **Pancreatic cancer:** Early-stage trial results for the vaccine following Folfirinox, an aggressive chemotherapy regimen, in cancer confined to the small ducts in the pancreas.

3. **Lung cancer:** Phase 3 results showing the efficacy of intismeran autogene alongside immunotherapy in patients with early-stage non-small cell lung cancer.

“The highest-profile presentation will showcase the results of a Phase 3 trial evaluating a combination of intismeran autogene and Merck’s Keytruda,” Barron’s noted. “An early look at the data in August showed the combined treatment prevented cancer from returning more effectively than Keytruda alone”.

Investors should expect volatility around the event. The August data release caused a massive move. The full data could either confirm the enthusiasm or raise questions.

---

## The Partnership with Merck: A Strategic Alliance

Intismeran isn’t a solo effort. It’s being developed in partnership with **Merck**, one of the world’s largest pharmaceutical companies.

The collaboration dates back years. Merck paid **$200 million upfront** to kick off the project and another **$250 million in 2022**. Under the current agreement, the companies **share costs equally** — including commercial, clinical, manufacturing, and capital expenditures — with remaining profit **split evenly**.

For Merck, the partnership is strategic. Keytruda, its blockbuster immunotherapy, has been the world’s best-selling drug for roughly three years. But it faces **loss of exclusivity in 2028**. Merck has been scrambling to expand its pipeline and secure new indications for Keytruda.

Intismeran could be the answer. If approved, it would shift Keytruda “from a drug facing a patent cliff into the cornerstone of a personalized platform”.

For Moderna, the partnership provides validation, resources, and commercial reach. Merck’s oncology salesforce is one of the most experienced in the industry.

---

## The Manufacturing Challenge: Scaling Personalization

Here’s the thing about personalized cancer vaccines: they’re incredibly difficult to manufacture at scale.

Unlike traditional vaccines, which are produced in massive batches, intismeran is **custom-made for each patient**. The process involves:

1. Collecting a patient’s tumor sample

2. Sequencing the DNA to identify unique mutations

3. Selecting the 34 most promising targets

4. Manufacturing a custom mRNA vaccine

5. Shipping it back to the hospital for administration

This is complex. It’s time-sensitive. And it requires coordination between Moderna, Merck, hospitals, and patients.

Bancel acknowledged the challenge at the Bernstein conference. He said the **principal bottleneck may be hospital operations** rather than manufacturing — particularly the ability to rapidly obtain biopsies and related patient information.

“Moderna and Merck are establishing teams to support hospitals and standardize those processes,” Bancel said. The companies have built a **digital platform** to track operational steps while maintaining patient privacy.

Moderna has also built a **purpose-built facility in Marlborough, Massachusetts**, specifically for intismeran manufacturing. The site is “designed for speed and scalability with advanced automation and robotics,” and began clinical batch supply in September 2025.

Bancel described intismeran manufacturing as “a synthetic, cell-free liquid process that can be scaled through smaller equipment footprints and faster cycle times”.

---

## Frequently Asked Questions

**Q: What caused Moderna stock to hit a new high this week?**

A: CEO Stéphane Bancel told investors at the Bernstein healthcare conference that Moderna is “an mRNA platform company,” not just a Covid vaccine maker. He highlighted the company’s expansion into oncology and rare diseases, including its personalized cancer vaccine, intismeran autogene. The stock hit a 52-week high of $192.31 on Wednesday and closed at $194.82 on Thursday.

**Q: What is intismeran autogene?**

A: It’s Moderna’s personalized cancer vaccine, developed in partnership with Merck. It’s engineered to flag dozens of mutations unique to each patient’s tumor. The vaccine is custom-made for each individual based on their cancer’s genetic profile.

**Q: How did the cancer vaccine perform in clinical trials?**

A: In August 2026, Moderna and Merck announced that a Phase 3 trial showed the vaccine, combined with Merck’s Keytruda, prevented melanoma from returning more effectively than Keytruda alone. The trial involved approximately 1,100 patients. The stock nearly tripled on the news.

**Q: What’s next for Moderna’s cancer vaccine?**

A: Moderna will present full data at the European Society for Medical Oncology (ESMO) Congress in late October 2026. The company is also planning to file for regulatory approval. Beyond melanoma, the vaccine is being studied in lung cancer, bladder cancer, pancreatic cancer, and other tumor types.

**Q: Is Moderna still a Covid vaccine company?**

A: Yes and no. Covid vaccines remain a significant part of Moderna’s business — the company has five approved products, including Covid and RSV vaccines. But CEO Bancel says the company “has never been” just a Covid vaccine company. It’s an mRNA platform company using its technology across infectious diseases, oncology, rare diseases, and autoimmune conditions.

**Q: What does the analyst community think about Moderna stock?**

A: Analysts are divided. According to 23 analysts polled by S&P Global, the consensus rating is **Hold**, with an average price target of **$119.56** — implying about **38% downside** from current levels. However, several firms have raised their targets following the cancer vaccine data, with some now in the $150-$170 range.

**Q: Why is there such a big gap between the stock price and analyst targets?**

A: The stock has rallied dramatically — up over 500% year-to-date — on the strength of the cancer vaccine data. Many analysts have been slow to update their models to reflect the full potential of intismeran. Some remain skeptical that the market opportunity justifies the current valuation. Others are waiting for more data before adjusting their forecasts.

**Q: What are the risks for Moderna investors?**

A: Key risks include: (1) **Execution risk** on the personalized cancer vaccine — manufacturing and commercializing a custom therapy at scale is extremely difficult. (2) **Tumor type variability** — the melanoma data was strong, but the vaccine may not work as well in other cancers. (3) **Competition** — other companies are pursuing mRNA cancer vaccines, though BioNTech recently scrapped a trial for its own candidate. (4) **Valuation** — the stock has already priced in a lot of optimism.

**Q: What is Moderna’s financial position?**

A: Moderna reported a net loss of **$1.3 billion** in Q1 2026. The company has cash and investments of approximately **$7.5 billion** (as of March 2026) and recently raised **$2.6 billion through convertible notes**. Revenue for 2026 is projected to grow up to 10% from 2025 levels.

**Q: What other products does Moderna have in development?**

A: Beyond the cancer vaccine, Moderna is developing:

- **mRNA-1083**, a flu + Covid combination vaccine (under review in Europe and Canada)

- **mRNA-1403**, a norovirus vaccine (Phase 3 ongoing)

- **Propionic acidemia treatment**, with pivotal data expected by year-end

- **Multiple rare disease programs** targeting liver diseases

- **In vivo CAR-T** and other autoimmune disease programs

**Q: When is Moderna’s next earnings report?**

A: Moderna is expected to report Q3 2026 earnings on **Thursday, November 5, 2026**.

**Q: Should I buy Moderna stock now?**

A: This article is not financial advice. Whether to buy Moderna depends on your individual financial situation, risk tolerance, and investment thesis. The stock has already rallied dramatically, and analysts are divided on whether the current valuation is justified. Do your own research and consider consulting a financial advisor.

---

## Conclusion: A Company Transformed

Here’s what I keep coming back to when I think about Karen, the portfolio manager in Boston.

She spent years trying to convince people that Moderna was more than Covid. She had the science. She had the pipeline. She had the vision. But nobody wanted to listen.

Now they’re listening.

The stock is up **over 500% this year**. It hit a new 52-week high this week. And the catalyst that drove the rally — a personalized cancer vaccine that could change how we treat cancer — is just beginning to show what it can do.

CEO Stéphane Bancel’s message at the Bernstein conference was simple: **Moderna was never a Covid company**. It’s an mRNA platform company. And the platform is now delivering results across multiple therapeutic areas.

The next few months will be critical. The ESMO presentations in late October will provide the full data on intismeran. The company is preparing for regulatory filings. And pivotal data for its rare disease program is expected by year-end.

For investors, the question is whether the current valuation reflects reality or hype. Analysts are divided, with some seeing significant downside and others believing the rally is just getting started.

But for Karen, the debate is settled. She saw the science before the market did. And now the market is catching up.

Moderna isn’t just a Covid vaccine company anymore. It’s a cancer vaccine company. A rare disease company. A platform company.

And the market is finally starting to believe it.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. The author has no position in Moderna (MRNA), Merck (MRK), or any related securities. Information presented here is based on publicly available sources and reported figures as of the publication date. Clinical trial results are not guarantees of future performance or regulatory approval. The stock market involves risk, including the potential loss of principal. Past performance does not guarantee future results. Always consult with a qualified financial advisor before making any investment decisions.**

Costco Wins $184M in Tariff Refunds, with More Expected

 Costco Wins $184M in Tariff Refunds, with More Expected

**The Warehouse Giant Just Got a Massive Check from the Government — And It's Giving Most of It Back to You**

---

## The Check That Came in the Mail

Let me tell you about a guy named Dave. He's a Costco member in suburban Phoenix. Been shopping there for fifteen years. Executive membership. Buys everything from bulk paper towels to rotisserie chickens to his kid's school snacks.

Dave doesn't follow earnings calls. He doesn't read SEC filings. He just knows that when he walks into Costco, he gets a good deal.

But last month, Dave noticed something. The price of his favorite Kirkland Signature Colombian coffee dropped. The walnuts he buys for his morning oatmeal got cheaper. Even the paper towels — the ones he buys in those giant packs — seemed to cost a little less.

He didn't think much of it. Just assumed Costco was running a sale.

What Dave didn't know was that he was benefiting from one of the most interesting corporate decisions of the year. Costco had just received a **$184 million refund** from the U.S. government for tariffs it had paid. And instead of pocketing the money, the company decided to give most of it back to members like Dave.

That's not just good business. That's a statement of values. And it's a story every American shopper should understand.

---

## The Numbers: What Costco Actually Received

Let's get the facts straight, because the details matter.

On September 24, 2026, Costco reported its fiscal fourth-quarter and full-year earnings for the period ending August 30 . Buried in those numbers was a line item that made investors and shoppers take notice: **$184 million in tariff refunds** received during the quarter .

That money broke down into two pieces: **$174 million in principal refunds** and **$10 million in interest** . The refunds stemmed from tariffs collected under the International Emergency Economic Powers Act (IEEPA) — tariffs that the Supreme Court ruled unlawful in February 2026 .

Costco's Chief Financial Officer, Gary Millerchip, told analysts on the earnings call that this initial payment represented **"a little more than one-third"** of the total refunds the company expects to receive . And here's the key detail: Costco had **already received a similar amount** in the first quarter of fiscal 2027 .

Do the math. If $184 million is one-third of the total, Costco is looking at roughly **$500 million or more** in refunds when all is said and done .

That's a lot of money. And it raises a question every Costco member should be asking: *What is the company going to do with it?*

---

## The Decision: Giving It Back

Here's where the story gets interesting.

Costco could have kept the refunds. It could have booked them as pure profit. It could have distributed them to shareholders through dividends or buybacks.

Instead, the company did something that says everything about its business model.

**Costco reinvested the majority of the refunds into lower prices for members** .

Chief Executive Officer Ron Vachris explained the logic during the earnings call. The company targeted items **"that would have the most impact for members"** — everyday products in produce, meat, and beverages, plus non-food items like home furnishings and hardware that had been hit hardest by the tariffs .

Millerchip put it simply: **"Our goal is to be the first to lower prices where we see opportunities to do so"** . He cited specific examples — reductions on Kirkland Signature walnuts, Colombian whole bean coffee, dry facial towels, and coarse black pepper .

This wasn't a marketing gimmick. It wasn't a temporary sale. It was a deliberate decision to pass tariff refunds through to the people who ultimately paid the tariffs in the first place.

---

## Why This Matters: The Economics of Tariffs

To understand why Costco's decision is so significant, you need to understand something about tariffs that most people don't realize.

**Tariffs are paid by American importers, not foreign companies.**

When the U.S. government imposes a tariff on imported goods, the importer of record — in this case, companies like Costco — pays the duty to U.S. Customs and Border Protection . The foreign manufacturer doesn't write a check. The American company does.

And here's the part that matters most: **those costs get passed on to consumers**.

Economists have studied this extensively. The Federal Reserve Bank of New York found that when tariffs increase the cost of imported goods, retailers pass a significant portion of those costs through to customers in the form of higher prices .

So when Costco paid tariffs on imported coffee, walnuts, furniture, and hardware, the cost didn't disappear. It showed up in the prices members paid at the warehouse.

When the Supreme Court ruled those tariffs unlawful, it created a pathway for importers to get their money back . Costco sued. It got in line. And now it's receiving refunds.

But here's the ethical question: *Who should get that money?*

Costco's answer was clear. The members who paid the higher prices should benefit. Not the shareholders. Not the executives. The members.

---

## The Lawsuit That Changed Everything

There's another layer to this story that makes it even more compelling — and more complicated.

Costco isn't just giving refunds back to members out of the goodness of its heart. The company is facing a **proposed class-action lawsuit** filed earlier this year .

The lawsuit alleges that Costco:

1. Raised prices due to tariffs

2. Represented that prices remained competitive

3. Failed to disclose that it intended to seek tariff refunds

4. Retained tariff refunds despite having passed the costs to customers 

The plaintiffs argue that Costco's retention of tariff refunds — after having shifted those costs to consumers — constitutes an unfair or deceptive act .

Costco hasn't commented publicly on the specifics of the litigation. But CEO Ron Vachris acknowledged during the earnings call that the company's decision to reinvest refunds into member value is connected to the legal proceedings. He said the specific amount and timing of future refund distributions will depend on **"how the refund litigation against the company develops"** .

So is Costco giving the money back because it's the right thing to do? Or because it's legally required to?

The honest answer is: probably both.

But here's what matters for members: **the money is coming back either way**. Whether motivated by ethics or legal pressure, Costco is passing tariff refunds through to the people who paid them.

---

## The Human Impact: What This Means for Your Wallet

Let's bring this back to Dave, the Costco member in Phoenix.

He noticed his coffee got cheaper. He noticed the walnuts cost less. He might not know why, but he's benefiting.

Millions of Costco members are in the same position. They're seeing lower prices on everyday items. They're getting more value for their membership fee. They're experiencing the tangible results of a corporate decision to prioritize customers over short-term profits.

And the scale of the refunds means this isn't over.

Costco has already received roughly **$370 million** in refunds — $184 million in Q4 plus a similar amount in Q1 of fiscal 2027 . If the total is indeed around $500 million or more, there's still another **$130 million or more** coming .

That means more price reductions. More value passed back to members. More reasons for Dave — and millions of others — to keep shopping at Costco.

---

## The Financial Picture: Strong Results Beyond the Refunds

It would be a mistake to think Costco's quarter was only about tariff refunds. The company delivered genuinely strong results across the board.

**Net sales for the quarter increased 11.2% to $93.9 billion**, up from $84.4 billion last year . For the full fiscal year, net sales hit **$297.2 billion**, a 10.1% increase .

**Net income for the quarter was $2.998 billion, or $6.75 per diluted share** — up from $2.610 billion, or $5.87 per share, last year . The tariff refunds contributed **$0.15 per diluted share** to that figure .

Strip out the one-time refund benefit, and Costco still grew earnings by **12.3%** . That's not a company relying on a government check. That's a company executing its core business exceptionally well.

**Membership fee income rose 7.3% to $1.849 billion** . Total paid members reached **84.1 million**, and paid executive members hit **42.3 million**, up 9.4% . Renewal rates improved to **92.3% in the U.S. and Canada** and **89.8% worldwide** .

**Digital sales grew nearly 20%** on a comparable basis, and Costco's partnership with Uber Eats for same-day delivery expanded from 17 states to nationwide .

And here's a demographic data point that's worth noting: **Costco members under 40 have increased nearly 60% since the pandemic** and now represent more than a quarter of the membership base . The company is attracting younger shoppers — a critical indicator for long-term health.

---

## Frequently Asked Questions

**Q: What exactly did Costco receive?**

A: Costco received **$184 million in tariff refunds** during its fiscal fourth quarter: $174 million in principal refunds and $10 million in interest . This represents a little more than one-third of the total refunds the company expects .

**Q: Why did Costco get these refunds?**

A: The refunds stem from tariffs imposed under the International Emergency Economic Powers Act (IEEPA). In February 2026, the Supreme Court ruled that the president lacked authority to impose tariffs under IEEPA, making the tariffs unlawful and creating a pathway for importers to seek refunds .

**Q: What is Costco doing with the money?**

A: Costco is **reinvesting the majority of the refunds into lower prices for members** . The company has reduced prices on everyday items in produce, meat, and beverages, as well as non-food items like home furnishings and hardware .

**Q: How much more is Costco expecting?**

A: The $184 million represents roughly one-third of the total. Costco has already received a similar amount in Q1 fiscal 2027. The total is estimated at **$500 million or more** .

**Q: Why is Costco giving the money back instead of keeping it?**

A: Two reasons. First, Costco's business model is built on delivering value to members — the company operates on thin merchandise margins and makes most of its profit from membership fees. Second, Costco faces a class-action lawsuit alleging it improperly retained tariff refunds after passing costs to consumers .

**Q: Is the class-action lawsuit connected to the refunds?**

A: Yes. The lawsuit alleges that Costco raised prices due to tariffs, then failed to disclose its intent to seek refunds, and retained the refunds despite having passed costs to customers . CEO Ron Vachris acknowledged that the refund distribution is connected to how the litigation develops .

**Q: How much will individual members get back?**

A: This isn't a direct cash payout. The refunds are being passed through **lower prices** on specific items. If the total refunds reach $500 million and are spread across 84.1 million paid members, that's roughly **$6 per member** — but delivered through price reductions rather than checks .

**Q: Which products have seen price reductions?**

A: CFO Gary Millerchip cited specific examples: **Kirkland Signature walnuts, Colombian whole bean coffee, dry facial towels, and coarse black pepper** . Reductions have also been applied to produce, meat, beverages, home furnishings, and hardware .

**Q: How did Costco's overall earnings look?**

A: Strong. Net sales rose **11.2%** to $93.9 billion for the quarter. Net income was **$2.998 billion, or $6.75 per share** — including the $0.15 per-share refund benefit. Excluding the refund, earnings still grew **12.3%** .

**Q: What about membership growth?**

A: Total paid members reached **84.1 million**, up 3.8%. Executive members hit **42.3 million**, up 9.4%. Renewal rates improved in both the U.S./Canada and worldwide .

**Q: Are other retailers doing the same thing?**

A: Walmart, Kroger, and Albertsons are also lowering prices using tariff refunds to fund investments in competitive pricing, according to reports . Costco isn't alone, but its commitment to passing refunds through to members has been particularly notable.

**Q: What should members watch for next?**

A: More price reductions as additional refunds arrive. Costco has said it will continue reinvesting the majority of refunds into member value . Watch for lower prices on items that were most affected by tariffs — particularly non-food categories like furniture and hardware.

---

## Conclusion: The Costco Difference

Here's what I keep coming back to when I think about Dave and his cheaper coffee.

Costco could have kept that $184 million. It could have booked it as profit. It could have boosted its earnings per share and made Wall Street happy.

Instead, it gave the money back.

Yes, there's a lawsuit. Yes, there's legal pressure. Yes, the company is protecting itself. But there's also something else happening here — something that explains why Costco has built one of the most loyal customer bases in American retail.

**The membership model creates alignment.**

Costco doesn't make its money on merchandise markups. It makes its money on membership fees. The company's entire business model depends on members renewing year after year. And members renew when they feel like they're getting value.

So when Costco gets a windfall from tariff refunds, the smart play isn't to pocket the money. It's to pass it back to members, reinforce the value proposition, and keep those renewals coming.

That's not charity. That's strategy. But it's the kind of strategy that benefits everyone — the company, the shareholders, and most importantly, the members who walk through those warehouse doors every week.

Dave doesn't know about the Supreme Court ruling. He doesn't know about the class-action lawsuit. He doesn't know about the earnings call or the CFO's comments.

He just knows his coffee costs less. And that's enough to keep him coming back.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or legal advice. The author has no position in Costco Wholesale Corporation (COST) or any related securities. Information presented here is based on publicly available sources and reported figures as of the publication date. The class-action lawsuit referenced is ongoing, and outcomes are uncertain. Anecdotal accounts are illustrative and do not represent specific individuals. Investing involves risk, including the potential loss of principal. Always consult with a qualified financial advisor before making any investment decisions.**

U.S. Treasury Yields Are Ending the Week Sharply Higher

 

U.S. Treasury Yields Are Ending the Week Sharply Higher

**The 30-Year Just Hit a 22-Year High. The 10-Year Touched 5.22%. And American Families Are About to Feel It in Ways They Didn't Expect.**

---

## The Week That Bond Investors Won't Forget

Let me tell you about a woman named Patricia. She's a retired schoolteacher in her late sixties, living in a modest house in suburban Sacramento. She's got a pension, some savings, and a portfolio of bonds her late husband set up years ago to generate steady income.

For most of her retirement, those bonds did exactly what they were supposed to do. They paid predictable interest. They didn't keep her up at night.

But this week? Patricia watched her bond portfolio lose value day after day. She doesn't fully understand yields and prices and basis points. But she understands the bottom line: her nest egg is shrinking, and nobody seems able to explain why.

"I called my broker twice," she told me. "He said something about the 30-year hitting a high. I said, 'A high of what? Is that good or bad?'"

It's bad. If you own bonds, or bond funds, or a target-date retirement fund with a bond allocation, this week hurt. And the pain isn't over.

---

## The Numbers: A Historic Selloff in Bonds

Let's get the data on the table, because this week's move in Treasuries was genuinely historic.

**The 30-year Treasury yield** climbed to **5.48%** during the week — its highest level since **2004**. That's a **22-year high**. 

**The 10-year Treasury yield** — the benchmark that influences mortgage rates, corporate borrowing costs, and just about everything else in finance — touched **5.225%** intraday, its highest since **July 2007**. 

**The 2-year Treasury yield**, which tracks what the market thinks the Federal Reserve will do with interest rates, climbed to **4.90%**, near a two-year high. 

The yield curve **steepened dramatically**, meaning long-term yields rose much more than short-term yields. The spread between the 10-year and 2-year hit its widest level since mid-month. 

This wasn't a one-day blip. The 10-year yield rose for a **sixth consecutive week** — its longest weekly losing streak since **November 2024**. 

And the selloff wasn't just in the U.S. Bond markets worldwide came under pressure. **Japan's 10-year government bond yield** hit its highest level since **1996**. **Germany's 10-year Bund** touched its highest in **17 years**. 

This is a global repricing of risk. And it's happening fast.

---

## Why This Is Happening: A Perfect Storm

To understand why Treasury yields are surging, you have to understand three forces that are all pulling in the same direction.

### Force #1: The Fed Is Done Cutting — And Starting to Hike

In mid-September, the Federal Reserve did something it hadn't done since **July 2023**: it **raised** interest rates. The federal funds rate went up by a quarter-point to **3.75% to 4.00%**. 

But the rate hike itself wasn't the shock. The shock was what the Fed signaled about the future.

The Fed's "dot plot" — a chart showing where policymakers expect rates to go — showed that most officials expect **at least one more hike this year**. The median projection for the end of 2026 jumped to **4.1%**, up from 3.9% in June. 

Fed Chair Kevin Warsh, who took over earlier this year, made it clear: the Fed is serious about fighting inflation, and it's not going to be pressured by politics.

"Reaching price stability eventually benefits workers," Warsh said at his press conference. "The economy is strong enough to handle this tightening." 

Traders got the message. By Friday, fed funds futures put the odds of **another rate hike in October at about 71%** — up from roughly even odds earlier in the week. Markets are now pricing in **close to four more quarter-point hikes** before this cycle ends. 

### Force #2: Oil Prices Are Surging — Again

If the Fed were the only problem, the bond selloff might be manageable. But it's not.

Oil prices are climbing, driven by the ongoing conflict with Iran and attacks on Saudi oil infrastructure. This week, **Houthi rebels attacked the Yanbu region near Saudi Arabia's border**, sending **WTI crude up nearly 5%** at one point. 

**Brent crude** settled around **$102 per barrel**, with intraday spikes higher. 

Here's why this matters for bonds: **oil prices feed directly into inflation**. When energy costs rise, businesses pay more to operate. Those costs get passed to consumers. Inflation expectations rise. And when inflation expectations rise, bond investors demand higher yields to compensate for the risk that their returns will be eroded.

The Fed's job gets harder, not easier, when oil is surging. And the market knows it.

### Force #3: The Economy Just Won't Slow Down

Perhaps the most surprising data point this week came from the **S&P Global U.S. Composite PMI**, a measure of business activity.

The September preliminary reading came in at **58.4** — up from 56 in August. That's the **highest level since July 2021**. Economists expected it to decline. Instead, it accelerated. 

The **new orders index** — a leading indicator of future activity — jumped to its highest since March 2022. And the **prices paid index** surged to **66.4**, the highest since **October 2022**, signaling that businesses are facing and passing on higher costs. 

Chris Williamson, chief business economist at S&P Global, put it bluntly: **"U.S. business activity continues to boom."** 

A booming economy sounds like good news. And in many ways, it is. But for bond markets, it's complicated. Strong growth means the Fed has less reason to cut rates. Strong growth means inflation pressure persists. Strong growth means the "risk-free rate" — the yield investors demand for lending money to the government — should be higher.

**Zachary Griffiths, head of investment grade strategy at CreditSights**, explained it well: **"You're seeing a repricing of several things — U.S. economic growth has remained resilient, and that's a more positive reason why you would find yourself in a higher risk-free rate environment."** 

---

## The Human Cost: What This Means for Real Americans

Let me bring this back to Patricia, the retired teacher in Sacramento.

She doesn't trade bonds. She doesn't follow the Fed. She just wants her retirement to be stable.

But here's what's happening to her, and to millions of Americans like her:

**If You Own Bonds or Bond Funds**

Bond prices fall when yields rise. That's the iron law of fixed income. If you own individual bonds and hold them to maturity, you'll get your principal back and you'll collect the interest payments. But if you own **bond funds** — which most retirement accounts do — the value of your holdings has declined this week.

The damage varies depending on what you own. Long-term Treasury funds have been hit hardest. Short-term bond funds have held up better. But almost everyone with a diversified portfolio has felt some pain.

**If You're Trying to Buy a Home**

Mortgage rates follow the 10-year Treasury yield. And the 10-year just hit 5.22%. **The 30-year fixed mortgage rate is now around 7%** — a level that has frozen the housing market. 

For buyers, every basis point increase in mortgage rates means higher monthly payments. A $400,000 mortgage at 6.5% costs about $2,528 per month. At 7%, it costs $2,661. That's **$133 more every month** — nearly **$1,600 a year** — for the same house.

And rates could go higher if Treasury yields keep climbing.

**If You're a Business Owner**

Corporate borrowing costs are tied to Treasury yields. When yields rise, it costs more for businesses to expand, invest, or refinance debt. Small businesses with floating-rate loans feel the pain immediately. Larger companies face higher costs when they issue new bonds.

**If You're a Saver**

Here's the one silver lining: **savings accounts, CDs, and money market funds are paying more**. If you have cash in the bank, you're finally earning meaningful interest. High-yield savings accounts are offering rates above 4%. Treasury bills are yielding even more.

For retirees like Patricia who have cash on the sidelines, this is a small consolation. For younger Americans building emergency funds, it's a genuine opportunity.

---

## The "6% Threshold": Why It Matters

Investors are now eyeing **6% on the 10-year Treasury yield** as the next potential pain threshold. 

Why 6%?

Because at that level, borrowing costs could start to **rattle financial markets and Corporate America** in ways that force a reckoning. 

Here's what happens when the 10-year hits 6%:

- **Mortgage rates could approach 8%**, effectively shutting down the housing market for anyone who doesn't have cash.

- **Corporate bond issuance could freeze**, as companies decide that borrowing is too expensive.

- **Equity valuations could compress**, because higher discount rates make future earnings less valuable today.

- **The Fed could face pressure to intervene**, either by slowing its tightening or by taking emergency measures.

We're not at 6% yet. But the speed of the move — the 10-year has risen **0.70 percentage points since June** and **1.25 percentage points since early March** — has investors nervous. 

**Gennadiy Goldberg, head of U.S. rates strategy at TD Securities**, broke down the drivers: **"The vast majority of the move higher in yields since March has been driven by rising Fed expectations, with the remainder driven by a combination of rising growth expectations and higher oil prices."** 

That's a lot of forces pushing in the same direction. And none of them are showing signs of reversing.

---

## Frequently Asked Questions

**Q: What exactly happened to Treasury yields this week?**

A: The 30-year Treasury yield hit **5.48%**, its highest since 2004. The 10-year touched **5.225%**, its highest since July 2007. The 2-year climbed to **4.90%**. Yields rose for a sixth consecutive week, marking the longest weekly losing streak for the 10-year since November 2024. 

**Q: Why are yields rising so fast?**

A: Three main factors: (1) The Fed raised rates in September and signaled more hikes to come. (2) Oil prices surged above $100 on Middle East tensions, feeding inflation fears. (3) Economic data — especially the S&P Global PMI — showed the economy is booming, not slowing, which supports higher rates. 

**Q: What does this mean for mortgage rates?**

A: Mortgage rates follow the 10-year Treasury yield. With the 10-year at 5.22%, the 30-year fixed mortgage rate is around **7%** — near its highest in two years. Further increases in Treasury yields could push mortgage rates toward 8%. 

**Q: Should I sell my bonds?**

A: This article is not financial advice. But generally speaking, selling bonds after a selloff locks in losses. If you hold individual bonds to maturity, you'll get your principal back. If you own bond funds, the value may recover if yields eventually fall. Consult a financial advisor about your specific situation.

**Q: Is this a bond market crash?**

A: The selloff is significant — the 30-year yield hitting a 22-year high is a major move. But "crash" implies panic and disorder. So far, the market has been orderly. Investors are absorbing higher yields because the underlying economy is strong and corporate profits are booming. 

**Q: What is the Fed doing about this?**

A: The Fed raised rates in September and signaled more hikes ahead. Fed Chair Warsh has emphasized that the economy is strong enough to handle tighter policy. However, if yields rise too far too fast, the Fed could face pressure to adjust its stance. 

**Q: Why is the 30-year yield hitting a 22-year high significant?**

A: The 30-year yield reflects investors' willingness to lend money to the government for three decades. When it rises this high, it signals that investors are demanding more compensation for long-term risks — including inflation, government debt, and fiscal uncertainty. It also directly affects 30-year mortgage rates. 

**Q: How does this affect the stock market?**

A: Rising yields pressure stock valuations by increasing the discount rate applied to future earnings. Growth stocks — especially tech — are most sensitive. However, stocks have held up relatively well this week, suggesting investors see the yield rise as driven by economic strength rather than crisis. 

**Q: Is this happening globally?**

A: Yes. Japan's 10-year yield hit its highest since 1996. Germany's 10-year Bund hit its highest in 17 years. The U.K. and Australia have also seen yields rise. This is a global repricing of bonds, driven by synchronized central bank tightening and energy-driven inflation. 

**Q: What should I watch next week?**

A: Key indicators include: (1) oil prices, (2) any new inflation data, (3) Fed speakers for clues about October, and (4) whether the 10-year breaks decisively above 5.25% or retreats. The 6% level is the big psychological threshold to watch. 

---

## Conclusion: A Week That Changed the Math

Here's what I keep coming back to when I think about Patricia, the retired teacher.

She called her broker, confused and worried. He tried to explain. But the truth is, the explanation doesn't make her feel better.

The world of finance is complicated. Yields, prices, basis points, dot plots — it's a language most Americans don't speak. But the consequences are felt in every household.

When Treasury yields rise, **mortgages get more expensive**. **Car loans get more expensive**. **Credit card rates go up**. **Businesses pay more to borrow**. **Retirement portfolios lose value**.

This week, the 30-year Treasury yield hit a **22-year high**. The 10-year hit its highest since **2007**. And the forces driving those moves — Fed tightening, surging oil, a booming economy — show no signs of reversing.

For bond investors, the pain may continue. For homebuyers, the dream is getting more expensive. For retirees, the nest egg is shrinking.

But for savers with cash, there's opportunity. For investors with patience, higher yields mean better long-term returns. And for the economy, the fact that all of this is happening without panic suggests something important: **the underlying foundation is strong**.

That doesn't make the pain less real. But it does mean this isn't 2008. It's not a crisis. It's a repricing.

The question is: how far will it go?

The 10-year Treasury yield is the most important number in finance. And right now, it's telling a story of an economy that refuses to slow down, inflation that refuses to die, and a Fed that refuses to blink.

Patricia doesn't need to understand all of that. She just needs to know whether her retirement is safe.

The honest answer is: it depends. On how much she owns in long-term bonds. On how long she can wait. On whether yields eventually come down.

That's not the answer anyone wants. But it's the truth. And in a week like this, the truth is the only thing that matters.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or trading advice. The author has no positions in any securities mentioned. Information presented here is based on publicly available sources and reported figures as of the publication date. Market conditions change rapidly, and bond prices and yields are subject to significant volatility. The anecdotal accounts presented are illustrative and do not represent specific individuals. Past performance does not guarantee future results. Investing involves risk, including the potential loss of principal. Always consult with a qualified financial advisor before making any investment decisions.**

GM, Ford to See US Market-Share Slide, Forecaster Predicts

 GM, Ford to See US Market-Share Slide, Forecaster Predicts

**Detroit’s Giants Are Losing Ground F

ast as American Buyers Flock to Hybrids, and One Analyst Says the Worst Is Yet to Come**

---

## The Warning Shot from the Motor City

Let me tell you about a guy named Rick. He owns a Chevrolet dealership just outside of Dayton, Ohio. His family has been selling GM vehicles for three generations. His grandfather opened the lot in 1962, back when Chevys were rolling off the line in Flint and Detroit was the undisputed king of the American road.

Rick is a loyal guy. He believes in the product. He believes in the brand.

But last month, something happened that shook him. A young couple walked into his showroom, fresh from a test drive of a Chevy Equinox. They liked it. They really did. Rick could see it in their eyes. They were ready to sign.

Then the husband asked a question that Rick has been hearing more and more lately: *“What’s the hybrid option?”*

Rick had to tell them the truth. GM doesn’t really make hybrids. Not like Toyota does. Not like Honda does. Not like Hyundai does.

The couple nodded politely, thanked him for his time, and walked out the door. Rick found out two weeks later they bought a Toyota RAV4 Hybrid from a dealer across town.

“I lost a sale because of a product we don’t have,” Rick told me. “And I’m going to lose a lot more.”

He’s not wrong. And a new forecast from one of the auto industry’s most respected research firms says things are about to get worse.

---

## The Forecast: A Reckoning for Detroit

On September 24, 2026, Cox Automotive released its quarterly industry forecast. And the headline was brutal for America’s two largest automakers.

According to Cox’s projections, **General Motors and Ford Motor will see their U.S. market share decline more than any other automakers this year**.

Here are the numbers that matter:

**Ford’s vehicle sales are expected to drop 8.8%** through the first three quarters of 2026. That would knock Ford’s market share down nearly a full percentage point, to **12.5%**.

**GM’s U.S. sales pace is trailing the broader industry**, expected to decline 6.2% year-to-date through September 30. Cox estimates GM will finish the quarter with a **16.7% market share**, down from 17.4% a year earlier.

Those are the two steepest market-share declines among 13 car companies tracked by Cox.

But the story goes deeper than just GM and Ford losing a little ground. It’s about the Detroit Three as a whole — GM, Ford, and Stellantis — falling to a historic low.

According to Cox senior economist Charlie Chesbrough, the combined market share of the Detroit Three is expected to hit **just over 36%** — the **lowest level on record**.

Meanwhile, Asian automakers are expected to account for **more than half of all U.S. new vehicle sales** for a second straight quarter, approaching record-high market share levels.

“The Detroit automakers are losing their grip on the American market,” Chesbrough wrote. And he expects the shift to continue through the end of the year.

---

## Why Is This Happening? The Hybrid Gap

So what’s driving this dramatic decline? The answer can be summed up in one word: **hybrids**.

Americans are paying more at the pump. Gas prices have been elevated for months, driven in part by the ongoing conflict with Iran that has disrupted global oil markets. When gas gets expensive, buyers look for fuel efficiency. And increasingly, they’re finding it in hybrids — vehicles that combine a gasoline engine with an electric motor to deliver dramatically better mileage without the range anxiety of a full EV.

The problem for GM and Ford? **They don’t have competitive hybrid offerings.**

Cox executive analyst Erin Keating put it bluntly during a media briefing: “GM has missed out on the hybrid story altogether, and so they’re really seeing some of their shares slide as well to the Toyotas, the Hondas, the Hyundais”.

For Ford, the situation is slightly different but equally painful. The company actually does offer some hybrids — notably the F-150 Hybrid and Maverick Hybrid. But Ford made a strategic decision to **discontinue the Escape compact SUV**, one of its most fuel-efficient offerings.

The Escape was a volume seller. It brought buyers into Ford showrooms. And it competed directly in the compact crossover segment, which is one of the hottest parts of the market. Without it, Ford lost a key entry point for fuel-conscious shoppers.

“Ford, you know, they lost the Escape,” Keating said. “They had some F-series production challenges, and then they had a deliberate pullback from rental volume”.

That F-series production challenge? It’s worth mentioning. A fire at an aluminum supplier earlier this year cut into Ford’s pickup truck output. Since the F-150 is Ford’s most profitable and highest-volume vehicle, any disruption there hits the bottom line hard.

---

## The Numbers Behind the Slide

Let’s look at the actual sales data to understand the magnitude of what’s happening.

**Ford’s First Quarter Was Rough**

Ford’s U.S. sales fell **9% year-over-year** in the first quarter of 2026, to 457,315 units. Truck sales dropped 11.3%. SUV sales decreased 7.8%. And electric vehicle sales plummeted **69.6%**.

The one bright spot? Ford maintained its position as America’s No. 1 truck brand. The F-Series sold 159,901 units, outperforming its closest competitor by 31,000 units. The F-150 Hybrid remained the top-selling full-size hybrid pickup, and the Maverick Hybrid led overall hybrid pickup sales.

But trucks alone can’t carry a company. Not when the rest of the lineup is struggling.

**GM’s Decline Was Even Steeper**

GM reported first-quarter sales of **626,429 vehicles**, a **9.7% decline** compared to the same period last year. In the second quarter, sales fell another 4.2% to 714,896 units, and first-half sales were down 6.8%.

GM still held the top spot in the U.S. market by volume. But its lead is narrowing.

**The Hyundai Threat Is Real**

Perhaps the most alarming data point for Ford came in August. For the **second consecutive month**, Hyundai Group outsold Ford Group when medium-heavy pickup trucks are excluded.

That’s not a fluke. Hyundai has been gaining ground steadily, and Cox predicts the Korean automaker will **overtake Ford in total quarterly sales** for the first time ever.

“This is not unprecedented — Hyundai Group outsold Ford Group for three consecutive months in 2021 — but the Korean OEM now appears to be challenging Ford Group’s volumes on a more regular basis”.

---

## The Human Cost: What This Means for Workers and Dealers

Behind every market-share percentage point is a human being whose livelihood depends on the auto industry.

**The Dealership Owner**

Rick, the Chevy dealer in Ohio, employs 47 people. Salespeople. Mechanics. Finance managers. Administrators. If his sales keep declining, he’ll have to make cuts.

“I’m not just selling cars,” he told me. “I’m supporting families. Every car I don’t sell is a mortgage payment that doesn’t get made, a kid’s braces that don’t get paid for.”

**The Factory Worker**

GM and Ford employ tens of thousands of American workers in manufacturing plants across the Midwest and South. If market share continues to slide, production cuts follow. And production cuts mean layoffs.

The UAW has been vocal about the threat. Union leaders have warned that the shift toward hybrids and EVs — and the corresponding decline of traditional powertrains — could reshape the workforce in ways that hurt communities that have depended on auto manufacturing for generations.

**The Small Business Owner**

Auto dealers aren’t the only ones affected. Parts suppliers. Logistics companies. Local restaurants that serve factory workers. Advertising agencies. The auto industry has a massive multiplier effect on local economies.

When Detroit sneezes, the Midwest catches a cold. And right now, Detroit is looking a little feverish.

---

## The Bright Spots: Where Ford and GM Are Still Winning

I want to be fair here. This isn’t a story of total collapse. Both companies have real strengths.

**Ford’s Truck Dominance**

Ford still sells more trucks than anyone else in America. The F-Series has been the best-selling vehicle in the country for decades. The F-150 Hybrid is a genuine differentiator — no other full-size truck offers a hybrid powertrain with that kind of capability.

Ford’s Bronco lineup is also performing well, with record first-quarter sales and strong demand for off-road trims. The Explorer remains the best-selling three-row SUV in America.

**GM’s EV Leadership**

GM has quietly become a serious player in electric vehicles. The company retained its position as the **industry’s second-largest EV seller** in the first quarter, behind only Tesla. Cadillac leads the luxury EV segment, and GMC achieved its best-ever first-quarter retail share.

GM has also signaled that it’s finally taking hybrids seriously. The company has announced plans to introduce plug-in hybrids to the U.S. market, a significant strategic shift after years of dismissing the technology.

**The Overall Market Is Actually Growing**

Here’s a counterintuitive point: Cox actually **raised its forecast for total U.S. vehicle sales** for the year, from 15.8 million to **16.1 million units**.

“Despite this volatile year, the new vehicle market has actually held up surprisingly steady,” Keating said.

So it’s not that Americans aren’t buying cars. They’re buying plenty. They’re just not buying as many GM and Ford vehicles as they used to.

---

## Frequently Asked Questions

**Q: What exactly did Cox Automotive predict?**

A: Cox forecast that Ford’s U.S. sales will drop **8.8%** through the first three quarters of 2026, reducing its market share to **12.5%**. GM’s sales are expected to decline **6.2%**, with market share falling to **16.7%**. These are the steepest declines among the 13 automakers Cox tracks.

**Q: Why are GM and Ford losing market share?**

A: The primary reason is a **lack of competitive hybrid offerings**. With gas prices elevated, American buyers are prioritizing fuel efficiency. Toyota, Honda, and Hyundai have strong hybrid lineups. GM has almost none. Ford discontinued the Escape, one of its most fuel-efficient vehicles.

**Q: Is Hyundai really going to outsell Ford?**

A: Cox predicts Hyundai Motor Group will overtake Ford in total quarterly sales for the first time ever in Q3 2026. Hyundai has already outsold Ford in two consecutive months when medium-heavy pickups are excluded.

**Q: What is the Detroit Three’s combined market share?**

A: Cox forecasts the combined market share of GM, Ford, and Stellantis will fall to **just over 36%** — the **lowest level on record**.

**Q: Are Asian automakers really taking over the U.S. market?**

A: Yes. Asian automakers are expected to account for **more than half of U.S. new vehicle sales** for a second straight quarter, approaching record-high levels.

**Q: What is GM doing to address the hybrid gap?**

A: GM has announced plans to introduce plug-in hybrids to the U.S. market. This is a significant strategic shift for a company that had previously focused almost exclusively on full EVs.

**Q: What happened to Ford’s F-Series production?**

A: A fire at an aluminum supplier earlier this year disrupted Ford’s pickup truck production. Since the F-Series is Ford’s most profitable vehicle line, this had an outsized impact on sales and market share.

**Q: Is the overall U.S. auto market shrinking?**

A: No. Cox actually **raised** its full-year forecast to **16.1 million units**, up from 15.8 million. The market is holding steady. GM and Ford are just capturing a smaller piece of it.

**Q: How did GM and Ford stocks react to the Cox forecast?**

A: The search results don’t include specific stock price data for the day of the announcement. However, market-share losses of this magnitude typically create headwinds for automaker stocks, as investors price in lower future earnings.

**Q: What does this mean for the U.S. economy?**

A: The auto industry is a major driver of American manufacturing and employment. If GM and Ford continue to lose market share, it could lead to production cuts, layoffs, and reduced economic activity in auto-dependent regions. However, the growth of Asian automakers with U.S. manufacturing footprints may offset some of those losses.

**Q: Should I buy GM or Ford stock?**

A: This article is not financial advice. Whether to invest in GM or Ford depends on your individual financial situation, risk tolerance, and investment thesis. Some analysts see value in these stocks due to low valuations and strong truck/EV businesses. Others are concerned about long-term market-share trends.

**Q: What should I watch going forward?**

A: Key indicators include: (1) whether GM’s plug-in hybrid plans materialize, (2) whether Ford introduces new hybrid models, (3) whether Hyundai’s momentum continues, and (4) whether gas prices remain elevated. These factors will determine whether the market-share slide continues or reverses.

---

## Conclusion: A Crossroads for Detroit

Here’s what I keep coming back to when I think about Rick, the Chevy dealer in Ohio.

He’s not angry at his customers for buying Toyotas. He understands why they do it. They want to save money on gas. They want reliability. They want a vehicle that fits their lives.

“I don’t blame them,” he told me. “I blame us. We should have seen this coming.”

That’s the painful truth at the heart of this story. The shift toward hybrids didn’t happen overnight. Toyota has been building hybrids for decades. Honda and Hyundai have invested billions in fuel-efficient technology. The writing has been on the wall for years.

GM and Ford made strategic choices. GM bet big on full electric vehicles, skipping hybrids entirely. Ford bet on trucks and SUVs, discontinuing the Escape and allowing its hybrid lineup to atrophy.

Those bets aren’t paying off in the current environment.

The good news is that both companies have time to adapt. GM is planning plug-in hybrids. Ford still dominates the truck market. Both have strong EV programs and loyal customer bases.

But the clock is ticking. Every month that passes without competitive hybrid offerings is another month of lost sales, another month of declining market share, another month of American buyers forming new habits with new brands.

For Rick, that means more difficult conversations with customers. More sales lost to Toyota and Honda and Hyundai. More uncertainty about the future of the dealership his grandfather built.

“I’m a Chevy guy,” he says. “I always will be. But I need Chevy to give me something to sell.”

The Motor City is listening. The question is whether it will act in time.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or business advice. The author has no position in General Motors (GM), Ford Motor (F), Toyota, Honda, Hyundai, Stellantis, or any related securities. Information presented here is based on publicly available sources and reported figures as of the publication date. Market conditions change rapidly, and forecasts are inherently uncertain. The anecdotal accounts presented are illustrative and do not represent specific individuals. Investing involves risk, including the potential loss of principal. Always consult with a qualified financial advisor before making any investment decisions.**